Drug intelligence / Profile preview

Synergy

Development stage: Unknown
Lead developer: Boston Scientific
Modality: Small Molecules, Device-based Delivery → Drug Delivery Systems

Overview

The SYNERGY Everolimus-Eluting Stent is a medical device, specifically a platinum chromium coronary stent system, featuring an ultra-thin abluminal bioabsorbable polymer coating that delivers the drug everolimus. The polymer and drug dissipate within approximately three months, aiming to promote rapid arterial healing and reduce complications associated with long-term polymer exposure. It is designed to improve coronary luminal diameter in patients with symptomatic ischemic heart disease, including those with acute myocardial infarction.

Brand names: SYNERGYSYNERGY IISYNERGY™-EESSYNERGY XDSYNERGY MEGATRON™
Other names: Everolimus-Eluting Stent (Synergy™)Bioabsorbable Polymer Drug-Eluting Stent

Targets

Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on Synergy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synergy.

Explore the full profile